Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
897
datasets available to search
ShareScore release 0.9.0
Dataset results
897 results for “Therapeutic targets”
Molecular Dynamics Simulation and Docking Studies Reveals Inhibition of NF-kB signaling as a Promising Therapeutic Drug Target for reduction in Cytokines Storms
<p><span>The complexes of the top identified molecules with NF-kB-kB site, as well as all the designed molecules used in the screening process. </span></p>
Dataset related to: Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy
<p>The files contain all the dataset included in the manuscript divided by figures.</p> <p> </p> <p>Abstract</p> <p>Alternative pathway complement dysregulation with abnormal glomerular C3 deposits and glomerular damage is a key mechanism of pathology in C3 glomerulopathy (C3G). No disease-specific treatments are currently available for C3G. Therapeutics inhibiting complement are emerging as a potential strategy for the treatment of C3G. In this study, we investigated the effects of N-acetylgalactosamine (GalNAc) conjugated small interfering RNA (siRNA) targeting the C3 component of complement that inhibits liver C3 expression in the C3G model of mice with heterozygous deficiency of factor H (Cfh+/- mice). We showed a duration of action for GalNAc-conjugated C3 siRNA in reducing the liver C3 gene expression in Cfh+/- mice that were dosed s.c. once a month for up to 7 mo. C3 siRNA limited fluid-phase alternative pathway activation, reducing circulating C3 fragmentation and activation of factor B. Treatment with GalNAc-conjugated C3 siRNA reduced glomerular C3d deposits in Cfh+/- mice to levels similar to those of wild-type mice. Ultrastructural analysis further revealed the efficacy of the C3 siRNA in slowing the formation of mesangial and subendothelial electron-dense deposits. The present data indicate that RNA interference mediated C3 silencing in the liver may be a relevant therapeutic strategy for treating patients with C3G associated with the haploinsufficiency of complement factor H.</p>
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
ClinicalTrials.gov study NCT02960659. IPD Sharing: YES. Countries: 1. Publications: 1.
Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC
ClinicalTrials.gov study NCT06639971. IPD Sharing: NO. Countries: 1. Publications: 3.
Liver-targeted polymeric prodrugs delivered subcutaneously improve tafenoquine therapeutic window for malaria radical cure
Open the record for dataset details and reuse information.
Opportunities for targeted therapies: trametinib as a therapeutic approach to canine oral squamous cell carcinomas
Open the record for dataset details and reuse information.
Therapeutic targeting of ATR in alveolar rhabdomyosarcoma
<p>Data related to the manuscript "Therapeutic targeting of ATR in alveolar rhabdomyosarcoma"</p> <p> </p> <p>It can be divided in three parts</p> <p><strong>Raw data from the phosphoproteomics screen (Raw data phosphoprot.7z)</strong></p> <p>Inside contains the following files:<br> Phosphopeptides in three replicates:</p> <ul> <li>Waldorf_20170621_KI_HS_314_phospho_1_L-ctrl_H-inh_NH4OH.raw</li> <li>Waldorf_20170621_KI_HS_314_phospho_1_L-ctrl_H-inh_pipe.raw</li> <li>Waldorf_20170621_KI_HS_314_phospho_2_L-ctrl_H-inh_NH4OH.raw</li> <li>Waldorf_20170621_KI_HS_314_phospho_2_L-ctrl_H-inh_pipe.raw</li> <li>Waldorf_20170621_KI_HS_314_phospho_3_L-inh_H-ctrl_NH4OH.raw</li> <li>Waldorf_20170621_KI_HS_314_phospho_3_L-inh_H-ctrl_pipe.raw</li> </ul> <p>Total proteome (three replicates):</p> <ul> <li>Waldorf_20170621_KI_HS_314_whole_1.raw</li> <li>Waldorf_20170621_KI_HS_314_whole_2.raw</li> <li>Waldorf_20170621_KI_HS_314_whole_3.raw</li> </ul> <p><strong>Raw data from the CRISPRa screen (CRISPR.7z)</strong></p> <p>Inside contains the following files:</p> <ul> <li>(control sample) flexbarOut_barcode_DMSO.fastq</li> <li>(treated sample) flexbarOut_barcode_AZD6738.fastq</li> </ul> <p><strong>Raw data from the RNAseq experiment (RNAseq.7z)</strong></p> <p>Inside contains the following files (NOTE: paired-end sequencing):</p> <ul> <li>(control sample) AH_HDG_1_S1_R1_001.fastq</li> <li>(control sample) AH_HDG_1_S1_R2_001.fastq</li> <li>(treated sample) AH_HDG_2_S2_R1_001.fastq</li> <li>(treated sample) AH_HDG_2_S2_R2_001.fastq</li> <li>(control sample) AH_HDG_3_S3_R1_001.fastq</li> <li>(control sample) AH_HDG_3_S3_R2_001.fastq</li> <li>(treated sample) AH_HDG_4_S4_R1_001.fastq</li> <li>(treated sample) AH_HDG_4_S4_R2_001.fastq</li> <li>(control sample) AH_YB_027_S7_R1_001.fastq</li> <li>(control sample) AH_YB_027_S7_R2_001.fastq</li> <li>AH_YB_028_S8_R1_001.fastq</li> <li>AH_YB_028_S8_R2_001.fastq</li> </ul>
Dataset for article: "Massively parallel de novo protein design for targeted therapeutics", DOI: 10.1038/nature23912
<p><strong>"Massively parallel de novo protein design for targeted therapeutics" </strong></p> <p>DOI: 10.1038/nature23912 </p> <p><strong>Supplementary Information</strong>. Archive of designs, Rosetta metrics and experimental results.</p> <p>Authors: <strong>Aaron Chevalier*</strong>, <strong>Daniel-Adriano Silva*</strong>, <strong>Gabriel J. Rocklin*</strong>, Derrick R. Hicks, Renan Vergara, Patience Murapa, Steffen M. Bernard, Lu Zhang, Kwok-ho Lam, Guorui Yao, Christopher D. Bahl, Shin-ichiro Miyashita, Inna Goreshnik, James T. Fuller, Merika T. Koday, Cody Jenkins, Tom Colvin, Lauren Carter, Alan Bohn, Cassie M. Bryan, D. Alejandro Fernández-Velasco, Lance Stewart, Min Dong, Xuhui huang, Rongsheng Jin, Ian A. Wilson, Deborah H. Fuller & <strong>David Baker</strong></p> <p><strong>*These authors contributed equally to this work</strong>.</p> <p>Correspondence to: dabaker@uw.edu</p> <p>Dataset Compiled by D-A.S.</p> <p>Date: 13/Sep/2017</p>
Supplemental files associated with the the manuscript "Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson's disease"
Open the record for dataset details and reuse information.
Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming
<p>Data underlying the figures in the publication “Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming”, published in <em>Nat Commun</em>, <strong>2020</strong>, 11, 608. <a href="https://www.nature.com/articles/s41467-020-14397-8">https://www.nature.com/articles/s41467-020-14397-8</a></p> <p>Table of contents:</p> <p><strong>1. Source Data</strong>; Excel file with the data for <em>Figures 2, 3b, 3d, 3c, 4a, 4b, 4c, 5</em> as well as <em>S2, S3, S4, S5, S6, S7a, S7b, S8, S9, S10, S11, S12, S13a</em> and <em>S13b</em>.</p> <p><strong>Data 1 – Transgene expression by SEAP</strong></p> <p>Data for <em>Figures 2, S2, S4, S5, S7a, S8, S9, S12</em> and <em>S13b</em>.</p> <p>SEAP (human placental secreted alkaline phosphatase) levels were profiled in cell culture supernatants using a colorimetric assay. 100 µL 2x SEAP assay buffer (20 mM homoarginine, 1 mM MgCl2, 21% diethanolamine, pH 9.8) was mixed with 80 µL heat-inactivated (30 min at 65 °C) cell culture supernatant. After the addition of 20 µL substrate solution (120 mM p-nitrophenyl phosphate; cat. no. AC128860100, Thermo Fisher Scientific, Waltham, MA, USA), the absorbance time course was recorded at 405 nm and 37 °C using a Tecan Genios PRO plate reader (cat. no. P97084; Tecan Group AG, Maennedorf, Switzerland) and the SEAP levels were determined as follows: first, absorbance change over time (slope) was calculated. According to the Beer–Lambert’s law, absorbance is proportional to the concentration of a colored compound and depends on the light path length (d) and extinction coefficient (ε) (ε for p-nitrophenyl (εpNP) = 18.600 M−1 cm−1). Enzymatic activity EA [U/L] was calculated from the equation: EA = slope × dilution factor × εpNP−1 × d−1</p> <p>Values in the file present determined SEAP levels.</p> <p><strong>Data 2 – Endogenous gene expression by qPCR</strong></p> <p>Data for <em>Figures 3b, 3d, 4a, 4b, 5, S3, S6, S10, S11</em> and <em>S13a</em>.</p> <p>Total RNA of HEK293T cells was isolated using the Quick-RNA kit (Zymo Research, Irvine, CA, USA). Reverse transcription was performed using a High-Capacity cDNA Reverse Transcription Kit (cat. no. 4368814, Thermo Fisher Scientific, Waltham, MA, USA). Quantitative PCR was performed with the SsoAdvanced Universal SYBR® Green Supermix (cat. no. 1725270, Bio-Rad, Hercules, CA, USA). The Eppendorf Realplex Mastercycler (Eppendorf GmbH) was set to the following amplification parameters: 30 s at 95 °C and 40 cycles of 15 s at 95 °C followed by 30 s at X °C (X = 59 for insulin, 64 for IL-12, 59 or 64 for GAPDH). The relative threshold cycle (Ct) was determined and normalized to the endogenous glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcript. The fold change for each transcript relative to the control was calculated using the comparative Ct method.</p> <p>Values in the file present determined mRNA levels relative to GAPDH.</p> <p><strong>Data 3 – Secreted protein level by ELISA</strong></p> <p>Data for <em>Figures 3c</em> and <em>4c</em>.</p> <p>Human Insulin was quantified with the Mercodia Insulin ELISA (cat. no. 10-1113-01, Mercodia, Uppsala, Sweden). IL-12 was quantified with the human IL-12 (p40) ELISA Kit (cat. no. KAC1561, Thermo Fisher Scientific, Waltham, MA, USA).</p> <p>Values in the file present protein levels as determined by ELISA kit.</p> <p><strong>Data 4 – Nanoluc luciferase</strong></p> <p>Data for <em>Figure S7b</em>.</p> <p>NanoLuc® luciferase was quantified in cell culture supernatants using the Nano-Glo® Luciferase Assay System (cat. no. N1110; Promega, Duebendorf, Switzerland). In brief, 7.5 µL of cell culture supernatant was added per well of a black 384-well plate and mixed with 7.5 µL substrate-containing assay buffer. Total luminescence was quantified using a Tecan Genios PRO plate reader (Tecan Group AG).</p> <p>Values in the file present luminescence as measured.</p>
Fig. 1. Figure showing the 2D in Geraniol and Citral as potential therapeutic agents targeting the HSP90 activity: An in silico and experimental approach
Fig. 1. Figure showing the 2D structural representation of lemongrass oil components (A–H). Component structures taken from Pubchem database.
Fig. 3 in Geraniol and Citral as potential therapeutic agents targeting the HSP90 activity: An in silico and experimental approach
Fig. 3. Pharmacophores of ligands H-bond interactions with receptor binding amino acid residues of human HSP90-ATPase binding with (A) ADP; (B) Geldanamycin; (C) Geraniol; (D) Citral; (E) Geranyl Acetate; (F) Methyl Eugenol; (G) Myrcene; (H) Elemicin.
Fig. 2 in Geraniol and Citral as potential therapeutic agents targeting the HSP90 activity: An in silico and experimental approach
Fig. 2. Docking scores of all screened ligands with HSP90 protein of humans (A), P. falciparum (B) and S. cerevisiae (C) which are showing the minimum free binding affinity (ΔG = kcal/mol).
Comprehensive analysis of the cuproptosis-related gene glutaminase across cancers: a potential prognostic therapeutic target for gliomas
<p><strong>Supplementary Table S1</strong> Clinical information of glioma patients.</p> <p><strong>Supplementary Table S2</strong> Top 100 genes associated with GLS.</p> <p><strong>Supplementary Table S3</strong> GO enrichment analysis data for GLS-associated genes.</p> <p><strong>Supplementary Table S4</strong> KEGG enrichment analysis data for GLS-associated genes.</p> <p><strong>Supplementary Table S5</strong> Antineoplastic drugs significantly associated with GLS.</p>
Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma
ClinicalTrials.gov study NCT00327197. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.
ClinicalTrials.gov study NCT03211325. IPD Sharing: UNDECIDED. Countries: 1. Publications: 25.
Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy
ClinicalTrials.gov study NCT07268833. IPD Sharing: Not stated. Countries: 1. Publications: 11.
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.
ClinicalTrials.gov study NCT04273932. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness
ClinicalTrials.gov study NCT06348693. IPD Sharing: Not stated. Countries: 1. Publications: 9.
PPAR-gamma: a Novel Therapeutic Target for Asthma?
ClinicalTrials.gov study NCT01134835. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.